These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 10926437)

  • 1. Prophylaxis and treatment of fungal infections associated with haematological malignancies.
    Ascioglu S; de Pauw BE; Meis JF
    Int J Antimicrob Agents; 2000 Aug; 15(3):159-68. PubMed ID: 10926437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evidence-based review of antifungal prophylaxis in neutropenic patients with haematological malignancies.
    Glasmacher A; Prentice AG
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i23-i32. PubMed ID: 16120631
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group.
    Morgenstern GR; Prentice AG; Prentice HG; Ropner JE; Schey SA; Warnock DW
    Br J Haematol; 1999 Jun; 105(4):901-11. PubMed ID: 10554799
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: a randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin B.
    Harousseau JL; Dekker AW; Stamatoullas-Bastard A; Fassas A; Linkesch W; Gouveia J; De Bock R; Rovira M; Seifert WF; Joosen H; Peeters M; De Beule K
    Antimicrob Agents Chemother; 2000 Jul; 44(7):1887-93. PubMed ID: 10858349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies.
    Cahuayme-Zuniga L; Lewis RE; Mulanovich VE; Kontoyiannis DP
    Med Mycol; 2012 Jul; 50(5):543-8. PubMed ID: 22103347
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label randomized trial comparing itraconazole oral solution with fluconazole oral solution for primary prophylaxis of fungal infections in patients with haematological malignancy and profound neutropenia.
    Glasmacher A; Cornely O; Ullmann AJ; Wedding U; Bodenstein H; Wandt H; Boewer C; Pasold R; Wolf HH; Hänel M; Dölken G; Junghanss C; Andreesen R; Bertz H;
    J Antimicrob Chemother; 2006 Feb; 57(2):317-25. PubMed ID: 16339606
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal prophylaxis with itraconazole oral solution in neutropenic patients.
    Kibbler CC
    Mycoses; 1999; 42 Suppl 2():121-4. PubMed ID: 10865918
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluconazole versus itraconazole for the prevention of fungal infections in haemato-oncology.
    Huijgens PC; Simoons-Smit AM; van Loenen AC; Prooy E; van Tinteren H; Ossenkoppele GJ; Jonkhoff AR
    J Clin Pathol; 1999 May; 52(5):376-80. PubMed ID: 10560360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic fungal infections in patients with hematologic malignancies: indications and limitations of the antifungal armamentarium.
    Böhme A; Karthaus M
    Chemotherapy; 1999; 45(5):315-24. PubMed ID: 10473919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravenous itraconazole compared with liposomal amphotericin B as empirical antifungal therapy in patients with neutropaenia and persistent fever.
    Yoshida I; Saito AM; Tanaka S; Choi I; Hidaka M; Miyata Y; Inoue Y; Yamasaki S; Kagoo T; Iida H; Niimi H; Komeno T; Yoshida C; Tajima F; Yamamoto H; Takase K; Ueno H; Shimomura T; Sakai T; Nakashima Y; Yoshida C; Kubonishi S; Sunami K; Yoshida S; Sakurai A; Kaneko Y; Miyazaki Y; Nagai H
    Mycoses; 2020 Aug; 63(8):794-801. PubMed ID: 32391919
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of primary antifungal prophylaxis in patients with haematological malignancies.
    Pagano L; Caira M
    Clin Microbiol Infect; 2014 Jun; 20 Suppl 6():19-26. PubMed ID: 24372659
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experience with itraconazole in systemic fungal infections.
    Boogaerts M; Maertens J
    Drugs; 2001; 61 Suppl 1():39-47. PubMed ID: 11219549
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A brief review of antifungal therapy for deep fungal infection.
    Muller RJ
    Oncology (Williston Park); 2001 Nov; 15(11 Suppl 9):21-5. PubMed ID: 11757847
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prophylaxis with itraconazole is more effective than prophylaxis with fluconazole in neutropenic patients with hematological malignancies: a meta-analysis of randomized-controlled trials.
    Wang J; Zhan P; Zhou R; Xu J; Shao X; Yang Y; Ouyang J
    Med Oncol; 2010 Dec; 27(4):1082-8. PubMed ID: 19876778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3,597 patients.
    Glasmacher A; Prentice A; Gorschlüter M; Engelhart S; Hahn C; Djulbegovic B; Schmidt-Wolf IG
    J Clin Oncol; 2003 Dec; 21(24):4615-26. PubMed ID: 14673051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fluconazole versus itraconazole for antifungal prophylaxis in neutropenic patients with haematological malignancies: a meta-analysis of randomised-controlled trials.
    Vardakas KZ; Michalopoulos A; Falagas ME
    Br J Haematol; 2005 Oct; 131(1):22-8. PubMed ID: 16173959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of fluconazole prophylaxis to reduce mortality or the requirement of systemic amphotericin B therapy during treatment for refractory acute myeloid leukemia: results of a prospective randomized phase III study. German AML Cooperative Group.
    Kern W; Behre G; Rudolf T; Kerkhoff A; Grote-Metke A; Eimermacher H; Kubica U; Wörmann B; Büchner T; Hiddemann W
    Cancer; 1998 Jul; 83(2):291-301. PubMed ID: 9669812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antifungal treatment strategy in leukemia patients.
    Büchner T; Roos N
    Ann Hematol; 1992 Oct; 65(4):153-61. PubMed ID: 1329995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emerging fungal pathogens, drug resistance and the role of lipid formulations of amphotericin B in the treatment of fungal infections in cancer patients: a review.
    Viscoli C; Castagnola E
    Int J Infect Dis; 1998-1999 Winter; 3(2):109-18. PubMed ID: 10225990
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Strategies for managing systemic fungal infection and the place of itraconazole.
    Potter M
    J Antimicrob Chemother; 2005 Sep; 56 Suppl 1():i49-i54. PubMed ID: 16120634
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.